Healthcare services provider Cardinal Health led a $35m series C round for Vineti, the US-based creator of an analytics software platform for personalised medicine, on Wednesday.
The round included pharmaceutical firm Novartis and Kite Pharma, a cancer immunotherapy subsidiary of biotech company Gilead Sciences, as well as Canaan Partners, Casdin Capital, LifeForce Capital, Threshold Ventures, Section 32, Hive Ventures and unnamed other investors.
Vineti has developed a cloud platform that helps developers of personalised therapeutics by integrating logistics, manufacturing and clinical data to help them manage and orchestrate complex operational processes.
The company will spend the series C proceeds on commercial growth and the further development of its software. It was co-founded by industrial technology producer General Electric and medical researcher and care provider Mayo Clinic.
Joe DePinto, president of Cardinal Health’s Specialty Solutions division, is joining Vineti’s board of directors while representatives of Novartis and Kite will take board observer positions.
DePinto said: “Cardinal Health has led the industry in partnering with manufacturers to bring cell and gene therapies to market. Our investment in Vineti reflects our continued commitment to targeted medicine and our excitement about collaborating with other industry leaders to support the growth of this exciting field.”
Vineti closed a $13.8m series A round in 2017 featuring corporate venturing units GE Ventures and Mayo Clinic Ventures in addition to LifeForce Capital and Threshold Ventures (then known as DFJ).
Threshold Ventures and Canaan Partners co-led the company’s $33.5m series B round the following year, investing alongside GE Ventures, Section 32, Casdin Capital and LifeForce Capital.
